Study for Evaluation of Safety and Efficacy of PADN to Treat Combined Post- and Pre- Capillary Pulmonary Hypertension Associated With Chronic Heart Failure

Heart Failure Clinical Trial

Official title:

Study for Evaluation of Safety and Efficacy of Pulmonary Artery Denervation to Treat Combined Post- and Pre- Capillary Pulmonary Hypertension Associated With Chronic Heart Failure: A Pilot Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05996562
• Other study ID #: Pulnovo-CO-2023-01
• Status: Not yet recruiting
• Phase: N/A
• Start date: December 2023
• Est. completion date: December 2024

Study information

• Verified date: August 2023
• Source: Pulnovo Medical (Wuxi) Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this pilot study is to evaluate the safety and efficacy of pulmonary artery denervation (PADN) in combined post- and pre- capillary pulmonary hypertension (CpcPH) associated with chronic heart failure(CHF).

Participants who have received guideline-directed medical therapy (GDMT) according to 2022 AHA/ACC Guidelines for Heart Failure (HF) and have been clinically stable for at least 1 month, will be treated with PADN and followed for 1 year.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 15
• Est. completion date: December 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age =18, =75 years;

2. CpcPH must be confirmed by RHC, defined as:

1. Mean pulmonary arterial pressure (mPAP) > 20mmHg;

2. Pulmonary capillary wedge pressure (PCWP) > 15mmHg;

3. Pulmonary vascular resistance (PVR) > 2WU;

3. Chronic heart failure has been diagnosed at least 3 months before screening and have been treated on the GDMT according to 2022 AHA/ACC Guidelines for Heart Failure for at least 1 month;

4. Clinically stable HF for at least 1 month, defined as:

1. No need of intravenous diuretics, inotropes or vasodilators, and

2. Systolic blood pressure (SBP) = 100 and < 160 mmHg, and

3. Resting heart rate (HR) = 50 bpm and <100 bpm (<110 bpm in presence of atrial fibrillation) on the day of the procedure.

5. NYHA class II-IVa;

6. 6MWD = 100 m and = 450 m;

7. NT-proBNP > 125pg/mL (or BNP > 35pg/mL);

8. Understand and be willing to sign informed consent and be strictly willing to follow the protocol.

Exclusion Criteria:

1. Any of the following:

1. Hypertrophic cardiomyopathy with left ventricular (LV) outflow tract obstruction and/or mitral valvular systolic anterior motion (SAM); or

2. Pericardial disease; or

3. Infiltrative or inflammatory myocardial disease; or

4. Valvular heart disease with stenosis or with severe regurgitation; or

5. Active endocarditis; or

6. Symptomatic carotid stenosis, or TIA or stroke within 30 days prior to randomization; or

7. Congenital heart disease; or

8. Having received any revascularization, including coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) within 6 months prior to randomization; or anticipated to undergo coronary revascularization (CABG or PCI) within 6 months; or

9. Artificial pacemakers, including single-chamber, dual-chamber and three-chamber pacemakers, have been implanted or are anticipated to be implanted within 6 months; or

10. Anticipated to undergo ablation of atrial fibrillation within 6 months; or

11. Anticipated to undergo heart valve surgery (valve replacement, valvuloplasty) within 6 months; or

12. Listing for heart/heart-lung transplantation or anticipated to implant a ventricular assist device (VAD)

2. Received pulmonary arterial hypertension (PAH) targeted drugs within 1 month prior to randomization;

3. Anticipated to undergo any surgery within the next 6 months;

4. Cardiac index (CI) measured by RHC < 1.5L/min/m2;

5. Severe renal insufficiency (eGFR < 30mL/min/1.73m2 by MDRD formula);

6. Severe liver insufficiency (Child-Pugh classification B-C);

7. Platelet count < 50 × 109/L;

8. Life expectancy < 1 year;

9. Systemic inflammation or other disease requiring long-term use of glucocorticoids or immunosuppressants;

10. Active infection requiring oral or intravenous antibiotics;

11. Cannot tolerate warfarin, aspirin, clopidogrel, and any of GDMT medicines;

12. Body mass index (BMI) > 40 kg/m²;

13. Pregnant or lactating women, or planning to be pregnant within one year;

14. Participation in other clinical trials within 3 months prior to signing the informed consent;

15. Any other circumstances that investigators deemed inappropriate to participate in this trial.

Related Conditions & MeSH terms

• Heart Failure
• Hypertension
• Hypertension, Pulmonary
• Pulmonary Hypertension

Intervention

Procedure:
• Pulmonary Artery Denervation
Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA. The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55°C for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Pulnovo Medical (Wuxi) Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	6-minute walk distance (6MWD) difference	The primary endpoint is change in 6-min-walk distance (6-MWD) from baseline to 6months.	6 months